Are you recommending tocilizumab for any COVID-19 patients?

Topics: Rheumatology • COVID-19 • Tocilizumab • COVID-19 virus

Current guidelines do not support its use, but the EMPACTA trial suggests it may be effective in a subpopulation of patients.

Answer from: at Community Practice

The utility of IL-6 receptor inhibitors in COVID-19 is controversial, and I do not recommend its routine use in COVID-19 patients at this time. Although early observational studies of IL-6 receptor inhibitors in severe COVID-19 suggested potential benefits, an early RCT of tocilizumab vs. placebo (B...

Comments

at University of Nevada - Las Vegas
The REMAP-CAP and EMPACTA trials emphasize that th...

at Northwestern Medical Group
I completely agree, and I anticipate there will be...

Related Questions